行情

PTLA

PTLA

Portola Pharma
NASDAQ

实时行情|Nasdaq Last Sale

7.13
+0.65
+10.03%
盘后: 7.13 0 0.00% 17:10 04/02 EDT
开盘
6.37
昨收
6.48
最高
7.35
最低
6.32
成交量
163.92万
成交额
--
52周最高
37.95
52周最低
5.31
市值
5.57亿
市盈率(TTM)
-1.7574
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PTLA价格均价为20.33,最高价位31.00,最低价为14.00。

EPS

PTLA 新闻

更多
  • Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire · 1天前
  • Portola Pharmaceuticals Option Alert: Apr 17 $7.5 Calls Sweep (3) near the Ask: 813 @ $0.3 vs 7860 OI; Earnings 5/6 Before Open [est] Ref=$6.48
  • Benzinga · 1天前
  • Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)
  • PR Newswire · 03/18 21:11
  • Edited Transcript of PTLA earnings conference call or presentation 26-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/17 19:10

所属板块

生物技术和医学研究
+3.32%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

PTLA 简况

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
展开

微牛提供Portola Pharmaceuticals Inc(NASDAQ-PTLA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PTLA股票新闻,以帮助您做出投资决策。